Pledging intellectual property for COVID-19
| Autor: | Mark A. Lemley, Jenny Molloy, Ariel B. Ganz, Frank Tietze, Jorge L. Contreras, Diane M. Peters, Michael B. Eisen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
2019-20 coronavirus outbreak
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Biomedical Engineering Bioengineering Public administration Intellectual property medicine.disease_cause Applied Microbiology and Biotechnology Pledge 03 medical and health sciences 0302 clinical medicine Development economics Pandemic medicine 030304 developmental biology Coronavirus 0303 health sciences Public health Convergence (economics) Molecular Medicine Business Commons 030217 neurology & neurosurgery Sudden onset Biotechnology |
| Zdroj: | Nature Biotechnology |
| ISSN: | 1546-1696 1087-0156 |
| DOI: | 10.1038/s41587-020-0682-1 |
| Popis: | COVID-19 differs from other recent public health crises with respect to its sudden onset, its rapid spread, the lack of any known vaccine or cure and resulting shortages of critical medical equipment. The convergence of these factors has prompted both governments and IPR holders around the world to seek ways to increase the availability of IPR necessary to combat the pandemic. Governmental compulsory licensing, IPR pools and voluntary IPR pledges have all been used in the past, though in situations that differ in important respects from the COVID-19 pandemic. Each is designed to result, to a greater or lesser degree, in a publicly-accessible “commons” of rights and technologies that are broadly available for use to support an important public health goals. Here, we compare and contrast these differing approaches to IPR commons formation and assess their suitability to address the COVID-19 crisis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink